

BIOCON GROUP

FINANCIALS

H1 FY 06 vs H1 FY 05

FACT SHEET

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT
(Rs. crores)

Particulars	H1 FY 2006	H1 FY 2005	Variance H1 FY 06 vs H1 FY 05	Full Year ended March 31, 2005
<u>INCOME</u>				
Sales-Biopharmaceuticals	291	287	1%	557
Sales- Enzymes	42	44	-5%	90
Contract research	42	29	45%	66
Total Sales	375	360	4%	713
Other income	2	7		15
Total Income / Revenues	377	367	3%	728
<u>EXPENDITURE</u>				
Manufacturing & other exp	265	245	8%	489
PBDIT /EBIDTA	112	122	-8%	239
Interest and finance charges	0	1		2
PBDT	112	121	-7%	237
Depreciation	15	9		22
PBT	97	112	-13%	215
Taxes	16	8		18
PROFIT FOR THE PERIOD	81	104	-22%	197
Add/(less): Minority interest	1	1		1
PAT	82	105	-22%	198
EPS on issued capital- (Rs)	8.2	10.5	-22%	19.8

NOTE: The figures are rounded off to nearest crores, percentages are based on absolute numbers

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		
Particulars	As at 30-Sep-05	As at 31-Mar-05
<u>SOURCES OF FUNDS</u>		
Share Capital	50	50
Reserves & Surplus	774	691
Total Shareholder's Funds	824	741
Minority interest	2	1
Deferred Tax Liability	23	23
Secured Loans	3	49
Unsecured Loans	32	27
Total Loan Funds	35	76
Total	884	841
<u>APPLICATION OF FUNDS</u>		
Fixed Assets (Net)	733	578
Investments	117	235
Inventories	89	74
Sundry debtors	213	183
Cash and bank balances	5	3
Loans and advances	16	17
Total Current Assets, Loans & Advances	323	277
Less: Current liabilities and provisions	289	249
Net Current assets	34	28
Total	884	841

BIOCON LIMITED (CONSOLIDATED)		
STATEMENT OF CASH FLOWS		<i>(Rs. crores)</i>
Particulars	Quarter ended Sept 30, 2005	Full Year ended March 31, 2005
<u>I. Cash Flow from Operating Activities</u>		
Net profit before tax	97	215
Less/Add: non-cash items/ items required separately		
Depreciation	14	22
Others	(1)	(10)
Changes in working capital and other provisions	4	(43)
Cash generated from operations	114	184
Tax paid (net of refunds)	(8)	(12)
Net Cash provided by operating activities	106	172
<u>II. Cash Flow from Investing Activities</u>		
Fixed Assets	(165)	(285)
Interest / dividend received	3	13
Investments	120	(213)
Net cash used for investing activities	(42)	(485)
<u>III. Cash Flows from Financing Activities</u>		
Proceeds from issuance of share capital (net of expenses)	0	0
Borrowings and other financing activities	(64)	(2)
Net Cash provided/(used) for financing activities	(64)	(2)
<u>IV. Net Change in Cash and Cash Equivalents (I+II+III)</u>		
	(0)	(315)
<u>V. Cash & Cash Eq. at the beginning of the year</u>	3	318
<u>VI CASH AND CASH EQUIVALENTS OF THE ESOP TRUST ACQUIRED DURING THE YEAR</u>	2	0
<u>VI. Cash and Cash Eq. at the end of the year (IV+V+VI)</u>	5	3